Valencia

• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul … Recruiting
  2023-503521-19-00 5 2024-02-09 Duchenne muscular dystrophy (DMD)
• Ph1/2 study of AVB-101 in Subjects with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) Recruiting
  2023-509444-10-00 7 2024-02-08 Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting
  2022-502514-86-00 1 2024-02-07 Myeloproliferative Neoplasms
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting
  2022-502741-10-00 7 2024-01-26 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH M … Recruiting
  2023-506572-27-00 3 2024-01-12 Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
• PHASE II CLINICAL TRIAL TO ESTABLISH THE SAFETY OF THE USE OF EXPANDED ALLOGENEIC FETAL UMBILICAL CORD STEM MESENCHYMAL CELLS IN PRETERM PAT … Recruiting
  2024-516677-79-00 4 2024-01-11 Premature patients with bronchopulmonary dysplasia
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV … Recruiting
  2023-505911-19-00 4 2024-01-05 Acute Myeloid Leukemia
• A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction Recruiting
  2023-503462-23-00 5 2023-12-28 Lung transplant rejection
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting
  2022-502984-39-00 5 2023-12-13 Severe Uncontrolled Asthma Asthma (an illness that causes breathing di
• International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting
  2022-501869-41-00 9 2023-11-14 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting
  2023-505385-28-00 4 2023-10-19 male or pre/post-menopausal women age ≥ 18 years with locally advanced
• A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting
  2023-504845-30-00 7 2023-10-05 Solid malignancies
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)

Showing 745–768 of 1,853 trials